tiprankstipranks
Trending News
More News >
Capha Pharmaceuticals (FPSUF)
:FPSUF
US Market

Capha Pharmaceuticals (FPSUF) AI Stock Analysis

Compare
1 Followers

Top Page

FP

Capha Pharmaceuticals

(OTC:FPSUF)

Rating:37Underperform
Price Target:
Capha Pharmaceuticals presents a highly risky investment proposition due to severe financial instability, lack of revenue, and reliance on debt financing. The technical indicators reflect an absence of market interest, and the negative valuation metrics further affirm the stock's unattractiveness.

Capha Pharmaceuticals (FPSUF) vs. SPDR S&P 500 ETF (SPY)

Capha Pharmaceuticals Business Overview & Revenue Model

Company DescriptionCapha Pharmaceuticals Inc. does not have significant operations. It intends to explore opportunities in the pharmaceutical distribution business. The company was formerly known as FPS Pharma Inc. and changed its name to Capha Pharmaceuticals Inc. in January 2017. Capha Pharmaceuticals Inc. was incorporated in 2004 and is based in West Kelowna, Canada.
How the Company Makes MoneyCapha Pharmaceuticals generates revenue primarily through the sale of its proprietary pharmaceutical products. The company invests heavily in research and development to bring new drugs to market, which are then commercialized and distributed globally. Key revenue streams include direct sales to healthcare providers, licensing agreements, and strategic partnerships with other pharmaceutical companies. Additionally, Capha Pharmaceuticals may receive milestone payments and royalties from collaborations with partners who leverage its research and development capabilities. The company's earnings are also supported by its intellectual property portfolio, which provides competitive advantages and potential for long-term revenue generation.

Capha Pharmaceuticals Financial Statement Overview

Summary
Capha Pharmaceuticals faces significant financial challenges, marked by zero revenue, escalating losses, and high leverage. The absence of revenue generation and reliance on debt financing underscore a precarious financial position, posing considerable risks.
Income Statement
1
Very Negative
Capha Pharmaceuticals shows no revenue generation across all periods, leading to a lack of profitability. The consistent negative figures for EBIT and Net Income indicate persistent operational losses without revenue growth potential.
Balance Sheet
1
Very Negative
The balance sheet is highly leveraged with a negative stockholders' equity, indicating insolvency risk. Total debt has increased significantly over the years, further heightening financial instability.
Cash Flow
2
Very Negative
The company consistently reports negative operating and free cash flows, suggesting insufficient cash generation to cover operations. Financing activities are the primary cash source, indicating reliance on external funding.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit0.000.00
EBITDA-58.56K-50.74K-53.22K-57.68K-44.49K-50.23K
Net Income-60.22K-70.77K-53.36K-58.31K-44.81K-51.16K
Balance Sheet
Total Assets1.82K1.80K1.75K
Cash, Cash Equivalents and Short-Term Investments1.38K653.00671.00
Total Debt560.07K560.07K489.07K416.07K338.07K276.57K
Total Liabilities581.27K572.32K501.49K317.34K282.01K234.27K
Stockholders Equity-579.45K-570.51K-499.74K-315.67K-278.52K-232.05K
Cash Flow
Free Cash Flow-63.95K-71.02K-73.36K-61.49K-47.38K-76.17K
Operating Cash Flow-63.95K-71.02K-73.36K-61.49K-47.38K-76.17K
Investing Cash Flow0.000.000.000.000.000.00
Financing Cash Flow63.50K71.00K73.00K59.91K49.05K74.93K

Capha Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$157.52B26.74105.67%3.25%15.59%56.99%
73
Outperform
$157.52B26.74105.67%3.25%15.59%56.99%
72
Outperform
$58.10B13.7015.96%0.65%7.52%15.65%
72
Outperform
$58.10B13.7015.96%0.65%7.52%15.65%
71
Outperform
$19.07B13.289.19%1.25%26.10%
71
Outperform
$19.07B13.289.19%1.25%26.10%
71
Outperform
$139.05B23.5032.51%2.83%4.63%1144.01%
71
Outperform
$139.05B23.5032.51%2.83%4.63%1144.01%
61
Neutral
$117.98B-5.64%8.55%-124.45%
61
Neutral
$117.98B-5.64%8.55%-124.45%
52
Neutral
$7.45B0.27-61.87%2.30%16.62%1.04%
37
Underperform
$64.0010.68%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FPSUF
Capha Pharmaceuticals
0.01
0.00
0.00%
AMGN
Amgen
297.00
-14.62
-4.69%
AMGN
Amgen
297.00
-14.62
-4.69%
BIIB
Biogen
133.02
-99.73
-42.85%
BIIB
Biogen
133.02
-99.73
-42.85%
GILD
Gilead Sciences
111.06
44.46
66.76%
GILD
Gilead Sciences
111.06
44.46
66.76%
REGN
Regeneron
547.75
-520.42
-48.72%
REGN
Regeneron
547.75
-520.42
-48.72%
VRTX
Vertex Pharmaceuticals
478.96
-12.66
-2.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 02, 2025